[Pharmacological treatment of pulmonary hypertension at a turning point].
Hiroshi
H
Watanabe
D000284:Administration, Oral; D000328:Adult; D000959:Antihypertensive Agents / Q000008:administration & dosage / Q000494:pharmacology; D000077300:Bosentan; D002243:Carbolines / Q000008:administration & dosage / Q000494:pharmacology; D065128:Endothelin Receptor Antagonists; D011464:Epoprostenol / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000494:pharmacology; D005260:Female; D006801:Humans; D006976:Hypertension, Pulmonary / Q000145:classification / Q000188:drug therapy* / Q000503:physiopathology; D007262:Infusions, Intravenous; D008297:Male; D010666:Phenylpropionates / Q000008:administration & dosage / Q000494:pharmacology; D058986:Phosphodiesterase 5 Inhibitors / Q000008:administration & dosage / Q000494:pharmacology; D010879:Piperazines / Q000008:administration & dosage / Q000494:pharmacology; D011651:Pulmonary Artery / Q000503:physiopathology; D011687:Purines / Q000008:administration & dosage / Q000494:pharmacology; D011724:Pyridazines / Q000008:administration & dosage / Q000494:pharmacology; D011743:Pyrimidines / Q000008:administration & dosage / Q000494:pharmacology; D016032:Randomized Controlled Trials as Topic; D000068677:Sildenafil Citrate; D013449:Sulfonamides / Q000008:administration & dosage / Q000494:pharmacology; D013450:Sulfones / Q000008:administration & dosage / Q000494:pharmacology; D000068581:Tadalafil; D014655:Vascular Resistance; D014665:Vasodilator Agents / Q000008:administration & dosage
D000959:Antihypertensive Agents; D002243:Carbolines; D065128:Endothelin Receptor Antagonists; D010666:Phenylpropionates; D058986:Phosphodiesterase 5 Inhibitors; D010879:Piperazines; D011687:Purines; D011724:Pyridazines; D011743:Pyrimidines; D013449:Sulfonamides; D013450:Sulfones; D014665:Vasodilator Agents; C048081:beraprost; D000068581:Tadalafil; D000068677:Sildenafil Citrate; D011464:Epoprostenol; C467894:ambrisentan; D000077300:Bosentan; C533860:macitentan